Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conestat Alfa for AKI Prevention in NSTEMI
NCT04912141Phase 2Terminated
- Sponsor
- Pharming Group
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of conestat alfa in acute kidney injury (AKI), sponsored by Pharming Group. Started Apr 2021; status: terminated.
02
Drugs
conestat alfa
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04912141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912141.